Home » Topics » IPO, BioWorld

IPO, BioWorld
RSS

Biopharma financings April 2025

Biopharma funding drops 71% from 2024, but in line with prior years

May 2, 2025

Total biopharma financings for the first four months of 2025 reached $15.48 billion, a 71% decline from $53.49 billion in 2024. Biopharma companies raised $2.4 billion in April 2025, reflecting a 37% drop from March's $3.82 billion.

China pharma migration: Hengrui greenlighted for Hong Kong IPO

April 28, 2025

By Marian (YoonJee) Chu

Jiangsu Hengrui Pharmaceuticals Co. Ltd. is the latest mainland China pharmaceutical company to seek a capital raise on the Hong Kong stock exchange, winning clearance April 28 from the China Securities Regulatory Commission to float new H-shares.

Chinabio 2025

US capital crunch pushes China biotechs to roundabout financings

April 24, 2025

By Marian (YoonJee) Chu

Tightening of U.S. regulation and capital is leading Chinese biotechs to alternative and new models of financing, ranging from cross-border licensing deals, M&As, the so-called newco model and overseas listings.

Duality Biotherapeutics raises $211M with Hong Kong IPO

April 16, 2025

By Marian (YoonJee) Chu

Antibody-drug conjugate developer Duality Biotherapeutics Inc. debuted on the Hong Kong Stock Exchange (HKEX) with a HK$1.64 billion (US$211.4 million) IPO April 15, making it one of the biggest offerings made under the HKEX’s Chapter 18A listing regime since 2020.

Biopharma financings 1Q25

Biopharma sees Q1 financings pullback, but private funding climbs

April 11, 2025

By Amanda Lanier

Biopharma companies brought in $13.08 billion in financing during the first quarter (Q1) of 2025, marking a significant drop from every quarter of 2024. The number of financings also declined, with 239 transactions completed in Q1 this year, down from a quarterly average of approximately 299 deals in 2024.

Biopharma financings March 2025

Private biopharma financings jump to $2B in March, up from $1B

April 4, 2025

By Amanda Lanier

Biopharma companies secured $3.82 billion across 81 public and private financings in March 2025, marking a 28% increase from the $2.98 billion raised through 59 transactions in February.

Visen announces HKD$603M Hong Kong IPO

March 14, 2025

By Tamra Sami

Visen Pharmaceuticals Co. Ltd. announced its initial public offering (IPO) on the Hong Kong Stock exchange (HKEX) to raise roughly HKD$603.3 million (US$77.6 million) to advance its pipeline of endocrinology assets.

Dualitybio among three to refile for Hong Kong IPO

Feb. 28, 2025

By Marian (YoonJee) Chu

Antibody-drug conjugate developer Duality Biotherapeutics Inc. is gearing up for a second IPO attempt this year, having filed on Feb. 27 a new prospectus on the Hong Kong Stock Exchange. Two other biotechs – Genuine Biotech Ltd. and Cloudbreak Pharma Inc. – also are having another go at a listing in Hong Kong in 2025.

DAC specialist Orum raises $35M with Kosdaq IPO

Feb. 14, 2025

By Marian (YoonJee) Chu

After withdrawing plans for an IPO last year, Orum Therapeutics Inc. made its debut on the Korea Exchange in 2025 with a ₩50 billion (US$34.7 million) raise as South Korea’s first biopharma IPO of the year.

Aardvark stock sinks first day; IPO to fund obesity drugs

Feb. 13, 2025

By Karen Carey

Raising $94.2 million in gross proceeds, Aardvark Therapeutics Inc. became the fifth biopharma company to list on Nasdaq so far in 2025.

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Science
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Asia
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

IPO, BioWorld RSS

IPO, BioWorld
RSS